微信小陈
微信小章
产品简介
购买须知
| 产品名称： | 13762 MAT B III |
|---|---|
| 商品货号： | TS214247 |
| Organism： | Rattus norvegicus, rat |
| Tissue： | mammary gland |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | suspension or loosely adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma |
| Strain： | Fischer 344 (F344) |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | The 13762 MAT B III cell line was established at the EG&G Mason Research Institute from a transplantable rat ascites tumor derived from the 13762 solid mammary adenocarcinoma. |
| Comments： | Prior to its deposit, the cell line was tested and found negative for the following viruses:
Pneumonia virus of mice (PVM), reovirus type 3 (Reo3), K virus, polyomavirus, Sendai virus, GDVII (mouse poliovirus), Kilham rat virus (KRV), minute virus of mice (MVM), SV5, H-1 virus and ectromelia virus.
The line grows as small clusters of rounded cells lightly attached to the substrate, or as a static suspension. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated McCoys 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Cultures are maintained by addition or replacement of fresh medium. Start new cultures at 1xa0x 105 viable cells/mL and maintain at 1xa0x 105 and 1xa0x 106 cells/mL.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| Name of Depositor： | AE Bogden |
| Deposited As： | Rattus sp. |
| References： | Xing RH, et al. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. 57: 3585-3593, 1997. PubMed: 9270032 |